In VC ‘Hat Trick’ for San Diego’s Avalon, RQx Inks Genentech Deal

2/12/13Follow @bvbigelow

RQx Pharmaceuticals, founded in 2010 to commercialize a scientific breakthrough with the potential to create a new class antibiotics, has signed a drug discovery collaboration with Genentech, the Roche subsidiary based in South San Francisco.

Genentech agreed to pay the San Diego startup an up-front payment, the amount of which was not disclosed, along with R&D milestone payments that could eventually total $111 million, according to a statement RQx issued today. The drug discovery startup says it also would be eligible to receive some royalties on sales revenue resulting from the collaboration.

The deal represents a strong endorsement for arylomycin, RQx’s lead drug candidate, and comes just a few months after CEO Court Turner told me he was seeking a strategic partner for the fledgling company. The deal with Genentech “went pretty rapidly after the initial conversation, which I want to say was in late September,” Turner said by telephone yesterday. “It was almost an instant marriage.”

It also marks the third successful life sciences deal in the first six weeks of 2013 for San Diego’s  Avalon Ventures, where Turner is a life sciences venture partner. That’s akin to scoring a hat trick in the first 10 minutes of a soccer game.

Just two weeks ago, Afraxis, another drug discovery startup in Avalon’s portfolio, said it had licensed its entire library of drug compounds to Genentech in a deal that could ultimately be worth as much as $187.5 million. A few weeks before that, BioMarin Pharmaceutical (NASDAQ: BMRN) acquired Avalon-backed Zacharon Pharmaceuticals for $10 million upfront plus potential milestone payments.

RQx Pharmaceuticals, arylomycinTo Avalon partner Jay Lichter, an industry veteran who worked with Turner at RQx, Avalon’s spate of deals is a testament to Avalon’s life sciences investment strategy, which he described as “early stage, high-risk science.” In many cases, Lichter said Avalon is the sole investor because its early stage deals look too much like a “crazy idea” to other venture investors.

Avalon was the sole investor in Zacharon and Afraxis, Lichter said, even though he worked hard to find other VCs to join in those funding deals. Both investments came out of Avalon’s eighth fund, which is better known for making a very successful bet on a social gaming startup called Zynga.

Yet of the seven life sciences investments Avalon made from its eighth fund, Lichter says only one—Incode BioPharmaceutics—was a loss. He described the firm’s investment in ReVision Therapeutics as a “push,” or break-even bet. Avalon has retained its investment stake in … Next Page »

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2

By posting a comment, you agree to our terms and conditions.